Jade Biosciences (NASDAQ:JBIO) Given New $39.00 Price Target at BTIG Research

Jade Biosciences (NASDAQ:JBIO) had its price target upped by BTIG Research from $28.00 to $39.00 in a research report report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also recently commented on the stock. HC Wainwright assumed coverage on shares of Jade Biosciences in a report on Wednesday, January 7th. They set a “buy” rating and a $25.00 price target on the stock. Zacks Research cut Jade Biosciences from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 10th. Lifesci Capital upgraded Jade Biosciences to a “strong-buy” rating in a research note on Friday, March 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. Finally, Wedbush reiterated an “outperform” rating and set a $24.00 price target on shares of Jade Biosciences in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.83.

Jade Biosciences Price Performance

NASDAQ JBIO opened at $14.25 on Monday. The company has a 50 day simple moving average of $14.68 and a 200-day simple moving average of $12.22. The firm has a market capitalization of $702.81 million, a price-to-earnings ratio of -3.09 and a beta of 1.03. Jade Biosciences has a 52-week low of $6.57 and a 52-week high of $100.10.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings data on Friday, March 6th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.34.

Hedge Funds Weigh In On Jade Biosciences

Hedge funds have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in shares of Jade Biosciences in the second quarter worth about $29,000. Russell Investments Group Ltd. bought a new stake in shares of Jade Biosciences during the 2nd quarter worth about $31,000. BNP Paribas Financial Markets acquired a new position in shares of Jade Biosciences during the 2nd quarter valued at about $32,000. Ameritas Investment Partners Inc. bought a new position in shares of Jade Biosciences in the 2nd quarter valued at approximately $33,000. Finally, California State Teachers Retirement System lifted its holdings in Jade Biosciences by 40.3% in the 4th quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after purchasing an additional 819 shares during the last quarter.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.